BioGDR predicts cell-line sensitivity to an ALDH1B1 inhibitor
BioGDR combines molecular structure with learned, predicted gene-expression and kinase-effect features and transcriptomic cell representations. Prospective in-vitro tests confirmed differential sensitivity to Golgicide A-2, including T84 colorectal cells (reported IC50 1.09 μM). This is a cell-line sensitivity result, not evidence of clinical benefit or discovery of the compound itself.
Technology: BioGDR multimodal interpretable deep learning; pathway graph attention
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The primary source reports the study-specific result summarized here.
- Still unknown: Independent replication and clinical benefit are not established by this source review.
- AI role: The model integrates predicted compound effects and cell transcriptomes to rank drug responses; the study prospectively tests candidate sensitivity in cell lines.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13396495/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source text reviewed; source_checks specify accessible sections..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.